RSVpreF Safe, Effective for Preventing Respiratory Syncytial Virus Illness in Seniors
MONDAY, April 10, 2023 (HealthDay News) — The respiratory syncytial virus prefusion F protein-based (RSVpreF) vaccine appears to be safe and effective for preventing RSV-associated lower respiratory tract illness in older adults, according to a study…
Learn MoreCDC Issues Warning as Two African Countries Fight Spread of Marburg Virus
FRIDAY, April 7, 2023 (HealthDay News) — Two ongoing outbreaks of Marburg virus in Africa prompted U.S. health officials to issue an alert on Thursday for doctors to be on the lookout for any cases that might surface in the coming weeks.The U.S. Cent…
Learn MoreRSVpreF Vaccine Found to Be Safe, Effective During Pregnancy
FRIDAY, April 7, 2023 (HealthDay News) — Receipt of bivalent respiratory syncytial virus prefusion F protein-based (RSVpreF) vaccine during pregnancy is safe and effective for preventing RSV illness in infants, according to a study published online A…
Learn MorePandemic Disrupted Respiratory Syncytial Virus Season Timing
FRIDAY, April 7, 2023 (HealthDay News) – The typical timing of seasonal respiratory syncytial virus (RSV) epidemics (October to April) was disrupted during the COVID-19 pandemic, according to research published in the April 7 issue of the U.S. Center…
Learn MoreCDC Issues Warning as Two African Countries Fight Spread of Marburg Virus
FRIDAY, April 7, 2023 (HealthDay News) – Two ongoing outbreaks of Marburg virus in Africa prompted U.S. health officials to issue an alert on Thursday for doctors to be on the lookout for any cases that might surface in the coming weeks. The virus cau…
Learn MoreCOVID-19 Infects Through Touched Surfaces in Homes, Study Confirms
FRIDAY, April 7, 2023 (HealthDay News) — For what they say is the first time, British researchers report that they have found the spread of COVID-19 in households is linked to the presence of the virus on hands and surfaces, not just in the air.The i…
Learn MoreLos anticuerpos monoclonales reducen las hospitalizaciones y muertes por la COVID en un 39 por ciento
MARTES, 4 de abril de 2023 (HealthDay News) — Los anticuerpos monoclonales han sido una herramienta efectiva en la batalla contra la COVID-19, y redujeron el riesgo de hospitalización o muerte en un 39 por ciento entre las personas que iniciaron el t…
Learn MoreMonoclonal Antibody Treatments Cut COVID Hospitalizations, Deaths by 39%
TUESDAY, April 4, 2023 (HealthDay News) — Monoclonal antibodies have been an effective tool in the battle against COVID-19, reducing the risk of hospitalization or death by 39% for people who started the treatment within two days of a positive test,…
Learn MoreNuevas pistas sobre un brote reciente de hepatitis en niños
VIERNES, 31 de marzo de 2023 (HealthDay News) — Una nueva investigación ha provisto respuestas a un misterio respecto a un brote de hepatitis grave en niños del año pasado.Surgieron alrededor de 1,000 casos en todo el mundo en primavera de 2022, desp…
Learn MoreUnas tasas bajas de vacunación ponen a EE. UU. en un alto riesgo de nuevos brotes de viruela símica
VIERNES, 31 de marzo de 2023 (HealthDay News) — Las autoridades de salud pública de EE. UU. quieren que los individuos con un riesgo alto que no se hayan vacunado contra la viruela símica (que en inglés se conoce ahora como mpox) lo hagan antes de un…
Learn More